Renalytix Share Discussion Threads

[74tom] 18/9/2020 07:16

So we’ve got the expected KidneyIntelX commercial launch RNS but nothing on the New York State approval ... very strange! I get that they are a minority owner of Kantaro but you’d think this was worth an RNS - either way it’s a double whammy of news, just need the FDA to follow suit now. I wonder whether Bio-Techne will RNS this afternoon?

[nimbo1] 18/9/2020 07:13

Thanks for update :)

[homebrewruss] 17/9/2020 21:33

Presumably yes, Renalytix tweeted it 1 minute after US market close.

[mr roper] 17/9/2020 21:20

Rns tomorrow then?

[homebrewruss] 17/9/2020 21:13

New York State Department of Health Grants Emergency Use Authorization to Mount Sinai for Quantitative COVID-19 Antibody Test



New York, NY (September 17, 2020) The Clinical Laboratories of The Mount Sinai Hospital has received emergency use authorization from the New York State Department of Health (NYSDOH) for quantitative use of Mount Sinai’s COVID-19 antibody test, making Mount Sinai’s lab the first in the country to run an authorized, fully quantitative antibody test that can deliver a precise numeric measurement of the level of antibodies in a patient’s blood. The value of an accurate, precise, and reliable antibody test that measures the level of antibodies an individual has cannot be underestimated. Such a test is urgently needed to help determine public health strategies and to accelerate both the development and evaluation of therapeutic treatments and vaccines.
“The Mount Sinai antibody test has been used on more than 68,000 patients, representing a highly diverse population due to the nature of our Health System, and gives us great confidence in the reliability and clinical relevance of the test,” said Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of the Lillian and Henry M. Stratton-Hans Popper Department of Pathology, Molecular and Cell-Based Medicine at the Icahn School of Medicine at Mount Sinai. “We have also used this testing with our essential workers to give insights into past infection rates and what levels of antibodies in people may ultimately be protective.”

In April 2020, the Mount Sinai antibody test was one of the first to receive emergency use authorization for qualitative use (detection of the presence or absence of antibodies) from both the U.S. Food and Drug Administration and the NYSDOH. The Mount Sinai antibody test detects the presence or absence of antibodies to SARS-CoV-2, the virus that causes COVID-19, in addition to measuring the titer (level) of antibodies a person has produced. It utilizes not one, but two virus antigens: the full-length spike protein and its receptor-binding domain (RBD), which is correlated with antibody neutralization, as described in a recent paper published in Nature Medicine. The test was used recently in a study by researchers at the Icahn School of Medicine at Mount Sinai that found most people with COVID-19 mount a robust antibody response that is stable for at least three months.

Created by a team of internationally renowned scientists and clinicians at the Icahn School of Medicine at Mount Sinai, the Mount Sinai antibody test is a serological enzyme-linked immunosorbent assay (ELISA) that was designed to measure the presence or absence of SARS-CoV-2 antibodies, in addition to measuring the titer (level) of antibodies a person has produced.

“One of the most important points is that what we measure in this assay correlates very well with virus neutralization. So, we can indirectly—and very easily—measure how well one person's serum can block and ultimately kill the virus without having to work with any infectious virus. That's amazing and allows us to measure thousands of samples per day,” said Florian Krammer, PhD, Mount Sinai Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai, who led the team that developed the antibody test.

"Our quantitative assay is being used to determine whether an individual has been exposed to SARS-CoV-2, to check their quantitative titers and eligibility for plasma donation, and to understand their antibody titers both in the initial response to SARS-CoV-2 and over time,” said Ania Wajnberg, MD, Director of the Antibody Donor Identification Program at Mount Sinai. “Eventually, this will help us link each individual's response to the immune correlate for COVID-19, which is a huge step forward in our fight against this virus."

[welshborderer] 17/9/2020 10:12

Hi All,
As a newbie forgive me if this has been posted elsewhere but note that while Halifax have credited the Dividend in Specie they will not allow it within an ISA. Anyone know if this can be challenged when circumstances change in the future?

This is their take on the situation and have credited the shares at a value of 1p per share:

RENALYTIX AI PLC - Important Information
Dividend in Specie.

1 Additional New Verici Dx Limited (Verici) Ordinary share for each Existing Renalytix AI Plc (Renalytix) share held on 10th July 2020, being the Ex-entitlement date.

On 7th July 2020, Renalytix announced its intention to distribute shares of its wholly-owned subsidiary Verici.

We can confirm that the additional Verici shares have been credited to your account.

Whilst the Verici shares are reflected on your account, under the terms of the distribution, the Verici shares are held in Trust on behalf of Shareholders for a period of up to 2 years, dependent on admission to trading on a recognised stock exchange. During this period, you will be unable to buy, sell or transfer the Verici shares.

Please note that as the Verici shares are held in Trust they are not eligible to be held within a ShareBuilder account, therefore we have taken the necessary steps to transfer the shares to your ShareDealing Account. In accordance with our Terms & Conditions, no fractions of shares have been transferred. All fractional holdings have been rounded down to the nearest whole share.

As Verici shares are not listed on a recognised Exchange, they do not qualify to be held within an ISA product under HMRC Guidelines. Therefore, if you held your New Verici shares in an ISA we have transferred these to your Share Dealing Account. If you did not have a Share Dealing Account, we have opened one for you.

We will notify you on receipt of any further information should an application be made to list the Verici shares on a Stock Exchange. Please be aware, however, that there can be no guarantee that any such application will materialise.

Should you wish to find more information about the Dividend in Specie, please visit the Renalytix website, hxxps://renalytixai.com/investors/

[nimbo1] 17/9/2020 10:09

renx have a huge global market and a shoe in from Mount Sinai - all they need to do is execute.

Physiomics I wouldn't touch with a barge pole.

[the stigologist] 17/9/2020 10:04

Looking like a huge Head and Shoulders no ?

Would recommend looking at Physiomics as a Cancer AI play which doesn't hae the hope value RENX has built in

[nimbo1] 17/9/2020 09:41

yep...but market wants an update on the commercialisation - they were excellent at keeping us updated during the IPO process (surprise surprise ; ))...not so much now! (Bear in mind we were told via analysts go live date was q2, then aug - now into sept...I don't mind push back as in real world these things are complicated but would appreciate an update!).

[74tom] 16/9/2020 14:41

Nice article posted by RENX on Twitter yesterday;



Also looking at some of their tweets from earlier this month, it appears the Mount Sinai launch of KidenyIntelx is in motion - so we will hopefully get an update on that alongside other news items before the end of the month...

[74tom] 10/9/2020 14:25

Indeed Wan, it feels like a long wait but when you consider what they’ve achieved since listing you’ve got to have every faith in them continuing to execute to plan.

[wan] 10/9/2020 10:07

Probably the same as the antibody test.....coming soon. And I am confident all things are in very capable hands.

[cambridgedon] 10/9/2020 09:22

Why did I think results were out today?
CD

[nimbo1] 09/9/2020 10:24

Market wants an update on commercialisation - was meant to happen in august...

[74tom] 04/9/2020 18:47

Thanks Wan. The evidence is certainly mounting for KidneyIntelX to be utilised asap, as usual I expect the newsflow to continue to be high impact. Interesting late trades from this afternoon, I was surprised at how well the bid hung on at 5.65 in light of the selling pressure, and now we can see the reason why... 2 x 35 k and a 65k bought at £5.75. Once these buys had been filled at 3.12pm, they plunged the price as the PI selling continued. £776k is no small investment.

[wan] 04/9/2020 16:23

I meant to post this up this morning (and got distracted) -

Mount Sinai Researchers Warn Increase in Chronic Kidney Disease Linked to COVID-19

In Retrospective Analysis, Researchers Review Data of Nearly 4,000 Patients Hospitalized with COVID-19

New York, NY (September 03, 2020) The results of a large -scale study of nearly 4,000 patients lead by researchers at the Icahn School of Medicine at Mount Sinai suggest that nephrologists will need to prepare for a significant uptick in patients with chronic kidney disease, the result of exposure to the SARS-CoV-2 virus that causes COVID-19. The study was published today in the Journal of the American Society of Nephrology.

“The sheer number of AKI cases, and the overwhelming need for dialysis that we are seeing in the context of COVID-19, is unprecedented. These findings may help health systems prepare for the high rates of renal dysfunction in incoming COVID-19 patients,” adds Dr. Nadkarni.

Full release -

[thesasquatch] 04/9/2020 12:42

My Verici shares are now showing in my x-o account. I chased them around two weeks ago

[wan] 03/9/2020 09:13

Charliee...Yes I tend to agree. Perhaps the fact that they are not allowed in an ISA is because they aren't UK listed shares in the full sense (yet). And therefore held outside of an ISA it would appear to potentially expose them (ultimately) to capital gains tax.

[charlieej] 03/9/2020 09:01

Agreed Wan and there is also the issue that those that have "received" shares are having them removed from their ISA. If we are given shares in the listed business when they are tradable I would hope that, akin to RENX distribution from EKF, the Verici shares will stay in the ISA. In this scenario receiving them now could be detrimental especially so if capital gains is increased. What do you think?

[busterdog2] 03/9/2020 08:51

Same as longshanks, but with the Halifax.

[wan] 03/9/2020 08:46

According to the announcements to date, I don't understand how we can expect to receive the shares yet, therefore I am also content to wait.

[faz] 03/9/2020 08:20

Verici: I have been in touch with AJ Bell over the last two weeks on the issue. I also challenged them re Halifax and yesterday wrote "The team have come back to me and confirmed they're unable to update the account with the expectation until we receive the physical shares. However, they have confirmed the ratio on this event will be 1 for 1" I'm fine with that and now expect them next July.

[longshanks] 02/9/2020 22:33

I am not with AJ Bell, but I got mine credited in iWeb a week or so ago. I wasn't allowed to have any in my ISA though so those got transferred into my main dealing account.

[toffeeman] 02/9/2020 17:03

CD - keep us AJ BEllers posted please!

[mw8156] 02/9/2020 17:00

Hfx has credited shares to an a/c